IXC

INVEX THER FPO [IXC]
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Healthcare · ASX Small Cap
$0.1150 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when IXC triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IXC — Free

Active Signals

Bullish Signals

  • Trading above both moving averages — the trend is your friend here
  • Volume surging at 21.3x normal while price falls — heavy selling pressure
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (36 quarters)
  • 4C filed 2026-07-23
  • Very high P/S ratio (184.6x)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.56%/day)
  • Altman Z-Score grey zone (2.98, low-confidence approx)
  • Liquidity risk: 8 zero-volume days in last 20
  • RBA hiking (-3pts)

Risk Signals

  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral

Expected next for IXC

24 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 11 Oct to 6 Nov
The last 10 moved IXC -2.8% on the day, on average — an observation, not a guide to what happens next.
25 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 25 Sep to 24 Nov
The last 10 moved IXC -2.8% on the day, on average — an observation, not a guide to what happens next.
28 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 15 Oct to 10 Nov
The last 10 moved IXC -2.8% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Appendix 4G and Corporate Governance Statement
LOW Appendix 4E and Annual Report to shareholders
LOW Quarterly Activities/Appendix 4C Cash Flow Report

Recent ASX Announcements

2026-08-31 Appendix 4G and Corporate Governance Statement
2026-08-31 Appendix 4E and Annual Report to shareholders PRICE SENSITIVE
2026-07-23 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$8.6M
Market Cap
43K
Avg Volume
21.3x
Vol Ratio
$0.09 — $0.18
52-Week Range
N/A
Short Interest
20 qtrs
Cash Runway
-29.5%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 61%
LLeader vs LaggardlaggardRS: -7
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:IXC vs NUZIXC vs IPDIXC vs HIQ
Share this analysis

Track IXC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required